Model‐Informed Dose Justifications of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection-Reference-Cited by-同舟云学术

Model‐Informed Dose Justifications of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection

Published:2022-12 Issue:4 Volume:63 Page:421-434
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharma

Author:

Iwasa Takashi¹,de Almeida Camila²,Fauchet Floris²,Winchell Gregory A.²,de Greef Rik²,Hasegawa Chihiro¹^ORCID,Yoshitsugu Hiroyuki¹,Wrishko Rebecca Ellen³

Affiliation:

1. Clinical Pharmacology Development MSD K.K Tokyo Japan

2. Certara Princeton New Jersey USA

3. Quantitative Pharmacology and Pharmacometrics Merck & Co., Inc. Rahway New Jersey USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.2180

Reference32 articles.

1. Molecular Dynamics Investigations of Binding Mechanism for Triazoles Inhibitors to CYP51

2. Single-Dose Phase I Study To Evaluate the Pharmacokinetics of Posaconazole in New Tablet and Capsule Formulations Relative to Oral Suspension

3. Effect of a High-Fat Meal on the Pharmacokinetics of 300-Milligram Posaconazole in a Solid Oral Tablet Formulation

4. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia

5. Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of Model-informed Drug Development (MIDD) in Regulatory Submissions for Drug Approval in Japan;2024-07-18

2. Clinical Pharmacology Strategy for Registration in Japan with a Case Example of Posaconazole, a Globally Approved Triazole Antifungal Drug with Broad-spectrum Antifungal Activity;Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics;2024-05-31

3. Factors Influencing Serum Posaconazole Concentrations in Patients With Hematologic Malignancies Receiving Delayed-Release Tablets;Therapeutic Drug Monitoring;2024-04-04

4. Personalized Antifungal Therapy Through Model-Informed Precision Dosing of Posaconazole;Clinical Pharmacokinetics;2024-03-26